Autologous Bone Marrow Mononuclear Cells Versus Allogenic Wharton Jelly-derived MSCs in Diabetic Chronic Limb-threatening Ischemia
Chronic Limb-threatening Ischemia · Diabetes Mellitus
Enrolment: 24 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Limb-threatening Ischemia · Diabetes Mellitus
Enrolment: 24 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 60 · Results not recorded
Type 2 Diabetes
Enrolment: 15 · Results not recorded
Rectal Cancer · Erectile Dysfunction
Enrolment: 34 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Non-exertional heatstroke under medetomidine 0.375 mg per kg, midazolam 2.0 mg per kg and butorphanol 2.5 mg per kg subcutaneously; rectal temperature raised approximately 1.0 degree Celsius every 5 minutes and held at 41.8 plus or minus 0.2 degrees Celsius for 30 minutes, then recovery at 24 degrees Celsius with 35 mL per kg subcutaneous saline to prevent dehydration
Bone marrow-derived mononuclear cells raised 7 day survival from 41.7 percent to 83.3 percent (p=0.021), lowered serum tumour necrosis factor alpha, histone H3 and syndecan-1, and reduced alveolar oedema and glycocalyx loss, although interleukin-6 and interleukin-1 beta reductions were not signific…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.